Medreleaf Recently Went Public, Becoming The Largest North American Pot Stock Ipo By Market Value Of All Time, While Its Competition Has Been Busy Expanding Grow Capacity In The Wake Of A Growing Number Of Medical Cannabis Customers And The Expectation Of Recreational Legalization. canopy Growth Corp.

For instance, a blood alcohol content of 0.08% or higher in the U.S. is considered impaired for a driver. There aren’t any guidelines for marijuana use, which makes resolving the concerns of lawmakers exceptionally challenging. A possible double-whammy for Canadian marijuana stocks If Canada is unable to get its recreational weed bill passed into law, Canadian marijuana stocks, which have risen considerably in anticipation of an expected legalization, could quickly lose the wind from their sails. The four, in particular, that are at greatest risk of having their valuations take a hit are Canopy Growth Corp. (NASDAQOTH: TWMJF), Aphria (NASDAQOTH: APHQF), Aurora Cannabis (NASDAQOTH: ACBFF), and MedReleaf (TSX: http://www.michiganmedicalmarijuana.biz LEAF). MedReleaf recently went public, becoming the largest North American pot stock IPO by market value of all time, while its competition has been busy expanding grow capacity in the wake of a growing number of medical cannabis customers and the expectation of recreational legalization. Canopy Growth Corp. acquired Mettrum Health earlier this year, widening its reach within Canada, and purchased 472,000 square feet of property, which also happens to house its headquarters. Meanwhile, Aurora Cannabis is working on a state-of-the-art 800,000 square foot facility known as Aurora Sky, and Aphria has moved onto its $100 million Phase IV expansion that’ll boost its grow capacity to one million square feet. These expansion figures sound great, if Canada moves forward with its recreational pot bill. If not, even with substantive growth in the medical cannabis market, there could be oversupply issues and weaker margins as a result.